Enovis
Logotype for Enovis Corporation

Enovis (ENOV) investor relations material

Enovis Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Enovis Corporation
Jefferies Global Healthcare Conference summary17 Nov, 2026

Market and growth outlook

  • Orthopedics remains a stable long-term market, with patient flow a tailwind; conditions were choppy over the prior 6–9 months, with European softness followed by U.S. slowing.

  • Consumer sentiment, inflation, payer scrutiny, deductibles and healthcare funding were cited as factors weighing on demand.

  • P&R is described as a diversified, relatively de-risked 3%–4% grower; 50% of its portfolio is growing at mid-single digits or more, with recovery in France and Germany an upside.

  • Recon growth would benefit from greater European stability; U.S. conditions were viewed as returning toward normal, and management characterized its forecasts as conservative.

P&R portfolio and services

  • OA products, the NOPAIN Act and cold therapy support product growth; MotionMD and MotionIQ account acquisition has been double-digit, with 99% customer satisfaction.

  • Revenue cycle management and clinic workflow services are key areas for portfolio expansion, supported by established brands and customer loyalty.

Recon execution and innovation

  • Commercial focus over the prior 7–12 months has included customer targeting, segmentation and funnel management, alongside integration of acquired product portfolios.

  • U.S. hip and knee growth was nearly 6% year to date versus a 3% market estimate cited by the analyst; the pipeline includes product launches for 2027 and 2028.

  • The EMPOWR knee franchise remains the main driver of U.S. knee outperformance and a door-opener for competitive conversions; robotic adoption is a challenge in account targeting.

  • Nebula hip instruments are gaining competitive accounts; a proprietary triple-tapered collared stem is planned for late 2027 or early 2028, with better gross margin than the current offering.

  • Shoulder portfolio compatibility across Prima, SMR and AltiVate is intended to give clinicians multiple approaches without switching suppliers; U.S. rollout is a key opportunity.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Enovis earnings date

Logotype for Enovis Corporation
Q4 202624 Feb, 2027
Enovis
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Enovis earnings date

Logotype for Enovis Corporation
Q4 202624 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Enovis Corporation is a medical technology company focused on developing innovative solutions for orthopedics and rehabilitation. The company designs, manufactures, and distributes medical devices, including braces, prosthetics, joint replacement implants, and rehabilitation equipment. Enovis serves healthcare providers, hospitals, and patients, offering products that support mobility, injury recovery, and surgical procedures. Enovis Corporation is headquartered in Wilmington, Delaware, and its shares are listed on the NYSE.